In triple-negative BC, elevated LILRB2 activated AKT/mTOR signaling to upregulate glucose transporter 3 (GLUT3) and pyruvate kinase muscle 2 (PKM2), thereby reprogramming aerobic glycolysis and enhancing tumor aggressiveness (Figure 4C) 337. The gene discussed is AKT1; the disease is neoplasm.